Gemcitabine


Opdivo ( Nivolumab ) 3 mg/kg plus Yervoy ( Ipilimumab ) 1 mg/kg ( injections for intravenous use ) was...



Pembrolizumab ( Keytruda ) was approved for the treatment of high-risk ( HR ) non–muscle-invasive bladder cancer ( NMIBC )...


Pembrolizumab ( Keytruda ) monotherapy has shown promising antitumor activity and manageable safety in patients with metastatic triple-negative breast cancer...


The European Commission has approved Talzenna ( Talazoparib ), an oral poly (ADP-ribose) polymerase ( PARP ) inhibitor, as monotherapy...


Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor...


The Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab), an anti-PD-1 ( programmed death receptor-1 )...


The aim of a study was to explore the efficacy and safety of Crizotinib ( Xalkori ) versus Platinum-based double...


Patients with epidermal growth factor receptor ( EGFR ) expressing advanced squamous non-small-cell lung cancer benefit most from Necitumumab (...


The idea that a non-Platinum therapy might artificially extend the Platinum-free interval, thereby improving outcomes in ovarian cancer patients who...


A study has compared the incidence of vascular thromboembolic events ( VTEs ) in patients with metastatic or unresectable urothelial...


Afatinib ( Giotrif ) was compared with standard Platinum-based doublet chemotherapy in two large, randomized phase III studies, ie, LUX-Lung...


Immune checkpoint blockade may play a role in the treatment of metastatic urothelial cancer ( mUC ). However, the role...


Cancer Drugs Fund ( CDF ) Panel has assessed the application for Eribulin ( Halaven ) to remain in the CDF...


Cancer Drugs Fund ( CDF ) Panel has assessed the application for single agent Pemetrexed ( Alimta ) to remain...


The European Medicines Agency's ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ) has adopted a...


The ASCO Task Force has applied the Framework to four clinical scenarios in which multiple trials have compared new treatment...


Combining Bevacizumab ( Avastin ) with first- or second-line chemotherapy in randomised phase III trials showed significantly improved progression-free survival...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a negative opinion, recommending the refusal of...